Legal disclaimer

The IV BUSULFEX Web site has been designed to provide general information about IV BUSULFEX. The information contained in this Web site is not intended to provide medical advice. The information presented on this Web site is not intended to replace medical advice offered by a healthcare provider. If you need medical advice or services, contact a physician or healthcare provider. Access and use of the IV BUSULFEX Web site is subject to the terms and conditions set forth herewith and all applicable laws, statutes and/or regulations. Otsuka America Pharmaceutical, Inc. may revise these terms and conditions from time to time by updating this posting.

Otsuka America Pharmaceutical, Inc. authorizes you to copy documents or pages published by us on this Web site for your noncommercial use only, provided any copy you make retains all copyright or other proprietary notices and any disclaimers contained herein. If you link to any other Web sites from this site, you should follow the copyright provisions contained in those sites.

All product names, regardless of whether or not they appear in large print or with a trademark symbol, are trademarks of Otsuka America Pharmaceutical, Inc., its licensees, or other third parties. The use or misuse of these trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, publication rights and communications regulations and statutes. Please be aware that Otsuka America Pharmaceutical, Inc. actively and aggressively enforces its intellectual property rights to the fullest extent of the law.

While Otsuka America Pharmaceutical, Inc. intends to periodically update this Web site, it makes no representations or warranties as to its accuracy or completeness. Access to and use of the content is solely at your own risk, and neither Otsuka America Pharmaceutical, Inc. nor any party involved in creating or delivering this Web site shall be liable for any damage of any kind arising out of the access, use or the inability to access or use this site, or for any omissions or errors contained in the Web site.

Any communication you transmit to Otsuka America Pharmaceutical, Inc. via this Web site or internet electronic mail is transmitted by you on a nonconfidential basis. Otsuka America Pharmaceutical, Inc. makes no promise, express or implied, not to use such communication or material for any purpose whatsoever, including reproduction, publication, broadcast and posting.

Certain links on this Web site lead to resources maintained by others over whom Otsuka America Pharmaceutical, Inc. has no control. As such, Otsuka America Pharmaceutical, Inc. does not adopt, endorse, opine or make any representation as to the truth, accuracy, legality or any other aspect of the information contained in those resources.

The only FDA-approved agent for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML)

Important Safety Information At the recommended dosage, IV BUSULFEX^® (busulfan) produced profound myelosuppression in all patients (ie, severe granulocytopenia, thrombocytopenia, anemia, or a combination thereof). Frequent complete blood counts should be monitored during treatment and until recovery. Hepatic veno-occlusive disease was diagnosed in 5/61 patients and was fatal in 2/5 cases. Anticonvulsant prophylactic therapy should be administered prior to treatment. Caution should be exercised in patients with a history of seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs. Bronchopulmonary dysplasia with pulmonary fibrosis is a rare but serious condition following chronic busulfan therapy. Women of childbearing potential should be advised to avoid becoming pregnant as busulfan may cause fetal harm.

The most common nonhematologic adverse events were nausea (92% mild or moderate, 7% severe), stomatitis (71% grade 1-2, 26% grade 3-4), and vomiting (95% mild or moderate), anorexia (64% mild or moderate, 21% severe), diarrhea (75% mild or moderate, 5% grade 3-4), insomnia (83% mild or moderate, 1% severe), and fever (78% mild or moderate, 3% life-threatening).

Please see Full Prescribing Information.